Table 5.
Hazard ratios of dying from breast cancer in relation to use of menopausal hormone therapy
Breast cancer deaths/exposed (n) | Mortality ratea | Hazard ratio (95% confidence interval)b | Hazard ratio (95% confidence interval)c | |
Never use | 230/1,491 | 1.9 | 1.0 (reference) | 1.0 (reference) |
Current used | 46/477 | 1.1 | 0.55 (0.40 to 0.77) | 0.63 (0.42 to 0.95) |
By duration | ||||
<5 years | 28/216 | 1.5 | 0.73 (0.48 to 1.13) | 0.76 (0.45 to 1.27) |
≥ 5 years | 18/260 | 0.8 | 0.42 (0.26 to 0.68) | 0.52 (0.29 to 0.93) |
By regimen | ||||
Estrogen-progestin | 37/391 | 1.1 | 0.54 (0.37 to 0.77) | 0.59 (0.38 to 0.91) |
Estrogen alone | 8/80 | 1.1 | 0.59 (0.29 to 1.20) | 0.78 (0.34 to 1.80) |
Past usee | 34/219 | 1.9 | 1.01 (0.71 to 1.45) | 1.03 (0.68 to 1.54) |
By duration | ||||
<5 years | 25/155 | 1.9 | 1.04 (0.69 to 1.58) | 1.02 (0.64 to 1.63) |
≥ 5 years | 9/64 | 1.7 | 0.94 (0.48 to 1.83) | 1.02 (0.48 to 2.17) |
Observations with missing information on menopausal hormone therapy, recent mammography, tumor size, or lymph node involvement excluded. aBreast cancer deaths per 100 person-years. bAdjusted for age at diagnosis (5-year categories), recent mammography (yes/no). cAdjusted for age at diagnosis (5-year categories), recent mammography (yes/no), adjuvant endocrine therapy (yes/no) and adjuvant chemotherapy (yes/no), tumor size, and lymph node involvement. dLast use <6 months before diagnosis. eLast use at least 6 months before diagnosis.